Human papillomavirus 18 E6-specific Affibody inhibits cervical cancer cell proliferation and induces apoptosis Authors: Haiyan Dong, Jing Zhang, Le Wu, Xi Zhang, Jun Chen, Wangqi Du, Saidu Kamara, Shanli Zhu, Lifang Zhang Published: 2026 ABSTRACT AbstractAbstractHuman papillomavirus (HPV) 18 E6 oncoprotein drives cervical carcinogenesis by degrading p53, enabling uncontrolled cell proliferation. In this study, we developed novel trans-activator of transcription (TAT)-conjugated Affibody molecules (TAT-ZHPV18E6) targeting HPV18 E6 for therapeutic applications. High-affinity Affibody variants were screened by phage display using recombinant HPV18 E6 expressed in Escherichia coli. Three candidates (TAT-ZHPV18E6: 4, 59, 352) exhibited high binding affinity, with equilibrium dissociation constant (KD) ranging from 10−6 to 10−4 M, with TAT-ZHPV18E6: 59 showing superior specificity for native HPV18 E6 in HeLa229 cells, as validated by surface plasmon resonance (SPR), enzyme-linked immunosorbent assay (ELISA), and immuno-fluorescence. In vivo near-infrared fluorescence imaging of DyLight 755-labeled TAT-ZHPV18E6: 59 in tumor-bearing mice demonstrated rapid tumor accumulation (peak at 2 h) and prolonged retention (> 12 h). Mechanistically, TAT-ZHPV18E6: 59 restored p53 stability and upregulated pro-apoptotic factors (Bax, PUMA) and cell cycle regulator p21. Notably, combined treatment with TAT-ZHPV18E6: 59 and E7-targeting TAT-ZHPV18E7: 228 combinatorial enhanced apoptosis and suppressed HeLa229 proliferation, as confirmed by CCK-8 and clonogenic assays. These results demonstrate the utility of TAT-ZHPV18E6 Affibody molecules as targeted agents, highlighting combinatorial E6/E7 targeting as a potent strategy for HPV18-driven cervical cancer therapy.Key points• TAT-ZHPV18E6: 59 achieved high affinity for HPV18 E6, enabling precise molecular targeting.• Demonstrates dual utility for in vivo imaging and p53-dependent tumor suppression.• Dual targeting of E6/E7 yields synergistic therapeutic efficacy in cervical cancer models.Keywords: Affibody molecules, HPV18E6, Cervical cancer, p53, Targeted therapy Introduction Persistent infection with high-risk human papillomavirus (HR-HPV), particularly types 16 and 18, is the primary etiologic factor for cervical cytopathia and cervical cancer (CC) (Saraiya et al. 2015; Kusakabe et al. 2023). Despite the implementation of preventive measures such as HPV vaccination and screening, CC remains the fourth most common cancer among women worldwide. In 2022, it was estimated to cause 660,000 new cases and 350,000 deaths globally (Jain et al. 2023; Bray et al. 2024). Current multimodal treatments, including surgery, chemotherapy, and radiotherapy, offer limited clinical efficacy for advanced-stage disease, which is often associated with tumor metastasis and poor prognosis (Hill 2020; Fleming 2023). Although immunotherapy has emerged as a promising strategy, monoclonal antibody (mAb)-based agents targeting programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1), human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor (EGFR) have demonstrated significant efficacy in several solid tumors, such as lung and breast cancers (Tang et al. 2022; Yang et al. 2023). However, effective CC-targeted agents remain limited (Ferrall et al. 2021; Wang et al. 2024). HPV early proteins are non-structural proteins essential for viral replication and oncogenesis. Among them, E6 and E7 are the key oncoproteins in HPV-associated CC. Mechanistically, E6 binds to the cellular ubiquitin ligase E6-associated protein (E6AP) to mediate degradation of the tumor suppressor p53. This process disrupts cell cycle and apoptosis while promoting genomic instability and telomerase activation, thereby contributing to cellular immortalization (Dymalla et al. 2009; Scarth et al. 2021). Concurrently, E7 binds to and inactivates the retinoblastoma protein (pRb), thereby releasing E2F transcription factors that promote uncontrolled cell proliferation and ultimately drive oncogenesis (Almeida et al. 2019). Additionally, E5 enhances the oncogenic potential of E6 and E7 by modulating growth factor receptors like EGFR (Scarth et al. 2021). Notably, E6 and E7 are selectively expressed in HPV-infected and transformed cells but absent in normal tissues (Pal et al. 2020), making them ideal targets for molecular imaging and targeted therapy of HPV-related tumors. Affibody molecules are engineered scaffold proteins derived from the immunoglobulin-binding Z domain of staphylococcal protein A (SPA) (Nilsson et al. 1987). By stochastically mutating 13 amino acid residues within the three-helical regions, vast combinatorial libraries have been constructed, allowing for target-specific selection through phage display (Ståhl et al. 2024). Compared with mAbs, Affibodies offer several advantages, including a small molecular size (6.5 kDa), rapid plasma clearance, superior tissue penetration, absence of Fc-mediated effects, and ease of labeling with fluorescein or biotin without compromising binding affinity. Despite their low molecular weight (1/25th of an IgG), Affibodies exhibit antibody-comparable affinity and specificity, making them excellent candidates for molecular imaging and targeted therapy (Ståhl et al. 2017; Barozzi et al. 2020). To date, Affibodies targeting over 50 distinct proteins have been reported, including those against HER2 (Orlova et al. 2006), EGFR (Wu et al. 2020), tumor necrosis factor-α (TNF-α) (Zhu et al. 2024), Epstein–Barr virus (EBV) latent membrane proteins (LMP1/LMP2) (Zhu et al. 2020), and HPV16 E6/E7 (Xue et al. 2016; Zhu et al. 2021). Notably, ABY-035, an IL-17-targeting Affibody, has demonstrated promising efficacy and safety in pivotal phase 3 clinical trials for psoriasis (Klint et al. 2023). As the first Affibody-based therapeutic to reach late-stage clinical development, its success underscores the significant translational potential of Affibody-derived agents for human disease intervention. In this study, we screened and identified high-affinity Affibody molecules targeting HPV18E6 oncoprotein using phage display technology, followed by prokaryotic expression. Their binding affinity and specificity for HPV18E6 were rigorously evaluated by enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), and in vivo near-infrared fluorescence (NIRF) imaging in CC xenograft models. Furthermore, the selected Affibody candidates significantly inhibited cell proliferation, induced apoptosis, and restored the p53 signaling pathway. Collectively, our findings demonstrate the potential of E6-targeting Affibodies as promising biological agents for the targeted therapy of HPV-associated CC. Materials and methods Materials Female BALB/c nude mice (4–6 week old) were purchased from GemPharmatech (Suzhou, China) and kept under specific pathogen-free (SPF) conditions at the Animal Facility of Wenzhou Medical University (Wenzhou, China). All animal procedures, including near-infrared fluorescence (NIRF) imaging, were approved by the Ethical Committee of Wenzhou Medical University (Ethics Review No. wydw2021-0585). Human CC cell lines (HPV18-positive HeLa229, HPV16-positive SiHa, and HPV-negative C33A) were obtained from American Type Culture Collection (ATCC; Manassas, VA, USA). Escherichia coli BL21(DE3) and the pET-21a(+) vector were purchased from ATCC and Novagen (Merck KGaA, Darmstadt, Germany), respectively. Primary mouse mAbs against HPV18E6 (Cat. No. sc-365089), p53 (Cat. No. sc-126), and PUMA (Cat. No. sc-374223) were obtained from Santa Cruz Biotechnology (Dallas, TX, USA). The mAbs against Bcl-2 (Cat. No. 15071), Bax (Cat. No. 36030), p21 (Cat. No. 2946), and β-Actin (Cat. No. 4970) were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-His-tag mouse mAb (Cat. No.66005-1-Ig) was obtained from Proteintech Group (Rosemont, IL, USA). Other analytical grade chemicals were purchased from Beyotime (Shanghai, China). Methods Preparation of targeting protein, recombinant HPV18E6 The recombinant pET-21a(+)/HPV18E6 plasmid was transformed into E. coli BL21(DE3) competent cells. Expression of recombinant His-tagged HPV18E6 protein was induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG; Sigma-Aldrich, St. Louis, MO, USA) at 37 °C for 6 h. Bacterial cells were lysed by ultrasonication, and the recombinant protein was purified using nickel-nitrilotriacetic acid (Ni-NTA) affinity chromatography (Qiagen, Hilden, Germany). Protein purity and identity were verified by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot (WB) analysis. Screening, modification, and expression of HPV18E6-targeting Affibody molecules The purified HPV18E6 protein was used to screen a random Affibody phage display library through three rounds of biopanning. Positive clones were selected by ELISA and DNA sequencing to identify HPV18E6 binding Affibody molecules, named ZHPV18E6. To enhance cellular uptake, the trans-activator of transcription (TAT) cell-penetrating peptide, derived from Human Immunodeficiency Virus (HIV-1; residues 49~57, GRKKRRQRRRPQ) (Wang et al. 2014), was fused to ZHPV18E6’s N-terminus by cloning into thepET-21a(+)-TAT vector. The resulting recombinant plasmid, pET-21a(+)-TAT/ZHPV18E6, and a control plasmid, pET-21a(+)-TAT/Zwt (encoding the original Affibody scaffold), were verified by sequencing and subsequently transformed into E. coli BL21(DE3) and expressed as hemagglutinin (HA) and His-tagged proteins. The purified TAT-ZHPV18E6 and TAT-Zwt proteins were analyzed by SDS-PAGE and WB, using an anti-His mAb as the primary antibody. Analysis of TAT-ZHPV18E6 target recognition and binding affinity and specificity The binding affinity of TAT-ZHPV18E6 was evaluated in vitro using ELISA and SPR and immunoprecipitation (IP). For ELISA, recombinant target HPV18E6-coated microplates were incubated with serially diluted TAT-ZHPV18E6, using TAT-Zwt as negative control and mouse anti-HPV18E6 antibodies as positive control. Binding affinity was detected using a horseradish peroxidase (HRP)-conjugated secondary antibody (Thermo Fisher Scientific, Waltham, MA, USA). SPR analysis was performed on a Biacore T200 system (Cytiva, Marlborough, MA, USA) with HPV18E6 immobilized on a Series S Sensor chip CM7 (Cytiva, USA). Real-time interactions were measured by injecting graded concentrations of TAT-ZHPV18E6 as previously described (Ramakrishnan et al. 2015). To validate endogenous binding specificity, HeLa229 cell lysates were immunoprecipitated using TAT-ZHPV18E6 protein as the capture reagent, followed by WB with anti-HPV18E6 mAb. The in vivo targeting specificity of TAT-ZHPV18E6 was quantitatively assessed using small animal NIRF imaging in tumor-bearing nude mice. Briefly, HeLa229 or SiHa cells (2 × 106 cells/mouse) were subcutaneously injected into the right scapular fossa of mice. Tumor growth was monitored every 3 days until reaching 300–500 mm3. Tumor-bearing mice were then administered with 50 µg (in 100 µL) of DyLight 755-labeled TAT-ZHPV18E6: 4 (59 or 352) or TAT-Zwt control via tail vein injection (n = 5 per group). In vivo distribution and metabolism of the proteins were assessed using a small animal imaging system (Maestro GNIR; CRI, Woburn, MA, USA) at 0 min, 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-injection. Determination of TAT-ZHPV18E6 half-maximal inhibitory concentration (IC50) The IC50 of TAT-ZHPV18E6 was evaluated using Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan). HPV18-positive HeLa229 cells were seeded in 96-well plates (5 × 103 cells/mL, 100 µL/well) and cultured for 24 h. Serial dilutions of TAT-ZHPV18E6:59 and TAT-Zwt (0, 8.13, 16.25, 32.50, 75.00, 150.00, 300.00 µg/mL) were then added (100 µL/well). After 72 h incubation, cells were treated with CCK-8 reagent (100 µL/well) for 2 h at 37 °C, and absorbance was measured at 450 nm using a microplate reader (ELx800; BioTek, Winooski, VT, USA). Cell viability was calculated as follows: cell viability (%) = [Atest − Bbackground]/[Ccontrol − Bbackground] × 100%. IC50 values were derived from dose-response curves using GraphPad Prism (version 9.0; GraphPad Software, San Diego, CA, USA). Assessment of the effects of TAT-ZHPV18E6 Affibody molecule on cell proliferation The effects of ZHPV18E6 on cervical cancer cell proliferation were evaluated using 5-ethynyl-2′-deoxyuridine (EdU) staining and colony formation assays. The EdU assay was performed using an EdU cell proliferation assay kit (Beyotime, Shanghai, China). HPV18-positive HeLa229, HPV16-positive SiHa, and HPV-negative (C33A) cells were treated with the following: (i) 100 µg/mL TAT-ZHPV18E6: 59 or TAT-ZHPV18E7: 228 (an HPV18E7-specific Affibody verified by our laboratory (Wang et al. 2019)), or TAT-Zwt, or (ii) a combination of 60 µg/mL TAT-ZHPV18E6: 59 and TAT-ZHPV18E7: 228 for 24 h, PBS as control. After 2-h incubation with 10 µM EdU (250 µL/well) at 37 °C, cells were fixed (4% paraformaldehyde (PFA), 20 min), permeabilized (0.3% Triton X-100, 10 min), and stained with Click reagent (100 µL/well, 30 min) and Hoechst 33342 (10 min). Fluorescence images were acquired using an inverted microscope (ZEISS, Oberkochen, Germany). The cell proliferation rate was measured as the ratio of EdU-positive cells (red) to total Hoechst-positive cells (blue). The colony formation assay was employed to further assess the impact of Affibody molecules on CC cell proliferation. HeLa229, SiHa, or C33A cells (1000 cells/well) were seeded in 6-well plates. After 48 h, cells were treated with the following: (i) 100 µg/mL TAT-ZHPV18E6: 59, TAT-ZHPV18E7: 228, TAT-Zwt, or (ii) a combination of 60 µg/mL TAT-ZHPV18E6: 59 and TAT-ZHPV18E7: 228 in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Grand Island, NY, USA) with 10% fetal bovine serum (FBS; Gibco). The medium was refreshed every 5 days. Visible colonies were fixed (4% PFA, 20 min), stained with 0.1% crystal violet (Beyotime, Shanghai, China) (30 min), and imaged, and representative colonies were imaged and quantified. Analysis of Affibody effects on apoptosis and cell cycle by flow cytometry Flow cytometry (FCM) was performed to evaluate Affibody effects on apoptosis and cell cycle progression in CC cells. HeLa229, SiHa, or C33A cells were treated for 24 h at 37 °C with the following: (i) 100 µg/mL TAT-ZHPV18E6: 59, TAT-ZHPV18E7: 228, or TAT-Zwt, or (ii) a combination of TAT-ZHPV18E6: 59 and TAT-ZHPV18E7: 228 (60 µg/mL each), with PBS as control. For apoptosis analysis, cells were trypsinized, washed with ice-cold PBS, and stained with 5 µg/mL Annexin V-fluorescein isothiocyanate/propidiumiodide (FITC/PI; BD Biosciences, San Jose, CA, USA) for 10 min in the dark before analysis on a CytoFLEX flow cytometer (Beckman Coulter, Indianapolis, IN, USA). For cell cycle analysis, ethanol-fixed cells (70%, −20 °C overnight) were stained with PI using the CycleTest Plus DNA Kit (Biotime, Shanghai, China) and analyzed by FCM (488 nm excitation) to detect DNA red fluorescence and light scattering. Analysis of the molecular mechanism of TAT-ZHPV18E6 To analyze whether TAT-ZHPV18E6: 59 blocks HPV18 E6-mediated degradation of p53, HeLa229 cells (1 × 105 cells/well) in 6-well plates were treated for 24 h at 37 °C with TAT-ZHPV18E6: 59 (5, 10, 20 µM), 20 µM TAT-Zwt (negative control), or PBS (mock control). Total proteins were extracted using RIPA buffer (Sigma-Aldrich, St. Louis, MO, USA). Protein concentrations were determined; WB analysis of p53 degradation (primary mAb anti-p53, 1:500) and downstream targets of p53 (primary mAbs: anti-Bcl-2, anti-Bax, anti-p21; all 1:1000) were detected, and β-Actin (1:1000) served as a loading control. Protein bands were visualized using an enhanced chemiluminescence (ECL) kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Statistical analysis Data are presented as mean ± standard deviation (SD) from at least three independent experiments. Statistical analyses were performed using GraphPad Prism (version 9.0; GraphPad Software, San Diego, CA, USA). Statistical significance was determined by one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test for multiple comparisons or Student’s t-test for comparisons between two groups, as appropriate. A p-value < 0.05 was considered statistically significant. Results HPV18E6 targeting protein was obtained with high purity The recombinant plasmid pET-21a(+)/HPV18E6 was successfully constructed and expressed in E. coli. Purified recombinant HPV18E6 protein (18 kDa) exhibited high purity as confirmed by SDS-PAGE, corresponding well with its theoretical molecular weight (Fig. 1), providing a reliable target for subsequent Affibody screening. Expression and purification of recombinant HPV18 E6 protein. A SDS-PAGE analysis (12% gel, Coomassie staining): Lane M: protein marker; Lane 1: uninduced E. coli BL21(DE3); Lane 2: empty pET-21a(+) vector; Lanes 3–4: pre- and post-IPTG induction of pET-21(+)/HPV18 E6; Lane 5: purified HPV18 E6. B Validation of HPV18 E6 (∼18 kDa) was further confirmed by Western blot analysis (anti-His as primary antibody) HPV18E6-targeting Affibody molecules were screened and selected Using phage display technology, a library with 1 × 107 capacity (42% accuracy, 100% diversity) was screened after three rounds of panning. Forty-eight ZHPV18E6-binding clones were identified through ELISA and DNA sequencing analysis. Three optional candidate monoclonal clones, designed as TAT-ZHPV18E6: 4 (GenBank accession No. PV737714), TAT-ZHPV18E6: 59 (GenBank accession No. PV730263), and TAT-ZHPV18E6: 352 (GenBank accession No. PV7370264), were finally selected based on their ELISA absorbance values and protein expression levels (Fig. 2A–C). Construction, expression, purification, and binding characterization of TAT-ZHPV18E6 Affibody molecules. A Schematic representation of the Affibody constructs featuring: N-terminal TATS cell-penetrating peptide (YGRKKRRQRRR), a central Z-domain scaffold derived from Staphylococcus protein A, and a C-terminal 6 × His-tag for purification. B SDS-PAGE analysis (15% gel, Coomassie staining) of purified Affibodies, Lane M: protein marker; Lanes 1–3: TAT-ZHPV18E6: 4, 59, 352 (approx. 9 kDa); Lane 4: TAT-Zwt control. C Western blot validation using anti-His mAb (1:5000 dilution), specific 9-kDa bands confirm expression integrity of all Affibody molecules. D ELISA dose-response curves quantifying binding to immobilized HPV18 E6. E‒H Surface plasmon resonance (SPR) sensorgrams demonstrating real-time binding kinetics for E TAT-ZHPV18E6: 4, F TAT-ZHPV18E6: 59, G TAT-ZHPV18E6: 352, and H TAT-Zwt (negative control) TAT-ZHPV18E6 targeting to HPV18 E6 were obtained with high binding affinity and specificity The binding affinity of TAT-ZHPV18E6 to HPV18 E6 was assessed by ELISA and SPR. ELISA revealed that TAT-ZHPV18E6: 4, 59, and 352 exhibited higher affinity with recombinant target protein HPV18 E6 than other clones (Fig. 2D). SPR analysis demonstrated that TAT-ZHPV18E6: 4, 59, and 352 all possessed high affinity for HPV18E6 protein, with equilibrium dissociation constant (KD) of 1.67 × 10−3 M, 3.76 × 10−6 M, and 2.80 × 10−5 M, respectively (Table 1; Fig. 2E–H), 102 to 104 times lower compared with control wild-type TAT-Zwt (6.27 × 10−2 M) (Fig. 2E–H). Table 1TAT-ZHPV18E6 Affibodies affinity analyzed by SPRKa (1/Ms)Kd (1/s)KD (M)TAT-ZHPV18E6: 44.2780.007121.67E-3TAT-ZHPV18E6: 595.378E + 30.020233.76E-6TAT-ZHPV18E6: 3521.442E + 30.040402.80E-5TAT-Zwt3.274E-20.002436.27E-2Ka, association rate constant; Kd, dissociation rate constant; KD, equilibrium dissociation constant TAT-ZHPV18E6 Affibodies affinity analyzed by SPR Ka, association rate constant; Kd, dissociation rate constant; KD, equilibrium dissociation constant IP results showed a distinct 18 kDa band (HPV18E6) after adsorbed and eluted by Protein A/G-beads (Beyotime, Shanghai, China) with TAT-ZHPV18E6 as the capture antibody, and mAb anti-HBV18E6 as detective antibody, whereas the control TAT-Zwt showed no binding. It indicated that there was good binding affinity and specificity between TAT-ZHPV18E6 and HPV18E6 protein (Fig. 3A, B). Binding specificity of TAT-ZHPV18E6 to HPV18 E6 and in vivo tumor targeting. A, B Immunoprecipitation and Western blot (WB) analysis. Lysates from HPV18-positive cells incubated withTAT-ZHPV18E6-conjugated Protein A/G beads, Lanes 1–3: eluates captured by TAT-ZHPV18E6: 4, 59, 352, respectively; Lane 4: control captured by TAT-Zwt, M: protein marker. A Short-exposure WB showing dominant 18-kDa HPV18 E6 band. B Long-exposure WB confirming absence of non-specific bands. C Coomassie-blue stained SDS-PAGE of purified DyLight 755-labeled Affibodies (> 95% purity). D, E In vivo NIRF imaging of tumor-bearing nude mice. Schematic of intravenous injection and imaging time points, the strong renal signal observe dictates renal clearance. D Specific accumulation in HPV18-positive HeLa229 xenografts at 2 h post-injection. Left: TAT-ZHPV18E6: 59 (strong tumor signal, yellow arrows); right: TAT-ZHPV18E6: 4 (minimal signal). E Absence of retention in HPV18-negative SiHa tumors (representative mouse shown) The tumor-targeting specificity of ZHPV18E6 was further evaluated in HPV18-positive (HeLa229) and HPV18-negative (C33A) tumor-bearing nude mice model using a small animal NIRF imaging. Following intravenous injection of DyLight755-conjugated TAT-ZHPV18E6 molecules (4, 59, or 352) and control TAT-Zwt, real-time fluorescence imaging revealed distinct biodistribution patterns (Fig. 3C–E). In HeLa229 models, TAT-ZHPV18E6: 59 and TAT-ZHPV18E6: 352 showed rapid tumor accumulation within 30 min, with signal intensity peaking at 2 h post-injection and maintaining strong tumor retention for over 8 h, while TAT-ZHPV18E6: 4 showed minimal signal. The strong renal signal was observed. In contrast, the SiHa tumor models only exhibited transient signal accumulation at 30 min post-injection, followed by complete signal clearance at 1 h. These results confirmed that the selected TAT-ZHPV18E6 molecules (particularly 59 and 352) exhibit high targeting specificity for HPV18E6-expressing tumor in vivo, with sustained retention capability. TAT-ZHPV18E6 inhibited proliferation of cervical cancer cell lines CCK-8 analysis demonstrated significant proliferation inhibition in HeLa229 cells treated with TAT-ZHPV18E6: 59 (half-maximal inhibitory concentration, IC50 = 10.56 µM) (Fig. 4A). Building on our previous finding that TAT-ZHPV18E7: 228 inhibited HeLa229 proliferation (Wang et al. 2019), we investigated the combinatorial effect of targeting both HPV18 oncoprotein E6 and E7. EdU incorporation and colony formation assays demonstrated significant proliferation inhibition in HeLa229 cells treated with TAT-ZHPV18E6: 59, TAT-ZHPV18E7: 228, or their combination compared to TAT-Zwt control (Fig. 4B–E). The combined treatment showed enhanced efficacy (p < 0.01). Notably, no inhibitory effects were observed in HPV16-positive SiHa or HPV-negative C33A cell lines. Flow cytometry results revealed that TAT-ZHPV18E6: 59, TAT-ZHPV18E7: 228, and their combination significantly enhanced apoptosis of HeLa229 cells compared to TAT-Zwt control protein (combination vs. control: 42.5% ± 3.8% vs. 6.2% ± 1.1%, p < 0.001) (Fig. 4F, G). No pro-apoptotic effects were observed in SiHa or C33A cells. Notably, none of the Affibody molecules induced significant cell cycle arrest in any cell line. TAT-ZHPV18E6: 59 inhibits proliferation of HPV18-positive cervical cancer cells. A Dose-dependent anti-proliferative effects of TAT-ZHPV18E6: 59. HeLa229 cells (HPV18-positive) were treated with increasing concentrations (0, 8.13, 16.25, 32.50, 75.00, 150.00, and 300.00 µg/mL) for 72 h, and cell viability was assessed by CCK-8 assay. The half-maximal inhibitory concentration (IC50 = 10.56 µM) was calculated using GraphPad Prism 9.0. B, C EdU incorporation assay (24 h): significant inhibition was observed in HeLa229 cells (**p < 0.01 vs. TAT-Zwt), while no significant effects were seen in HPV16-positive SiHa or HPV-negative C33A cells (p > 0.05). Enhanced suppression in HeLa229 with combined TAT-ZHPV18E6: 59 + TAT-ZHPV18E7: 228 (**p < 0.01 vs. TAT-Zwt). D, E Colony formation assay: strong suppression in HeLa229 cells by TAT-ZHPV18E6: 59 (**p < 0.01) and combinatorial treatment (TAT-ZHPV18E6: 59 + TAT-ZHPV18E7: 228, **p < 0.01), no significant inhibitory effects were observed in SiHa or C33A cells. F Flow cytometry analysis of apoptosis induction. Significant apoptosis was induced in HeLa229 by TAT-ZHPV18E6: 59 (27.33% ± 3.21%) and its combination with TAT-ZHPV18E7: 228 (35.13% ± 4.26%), whereas no significant apoptosis was detected in SiHa or C33A cells. TAT-Zwt was used as control. G Quantification of apoptotic cells. In HeLa229 cells, treatment withZHPV18E6: 59 and its combination withTAT-ZHPV18E7: 228 induced a significant fold-increase in apoptosis compared to the control (**p < 0.01). No significant changes were observed in SiHa or C33A cells TAT-ZHPV18E6 :59 restored p53 pathway by targeting HPV18E6 Among the three selected Affibodies, TAT-ZHPV18E6: 59 exhibited the highest binding affinity and specificity and was chosen for mechanistic investigation. WB analysis demonstrated that TAT-ZHPV18E6: 59 dose-dependently inhibited HPV18E6-mediated degradation of p53, resulting in increased p53 protein levels (Fig. 5). Consistent with p53 stabilization, the expression of downstream targets, including pro-apoptotic factors Bax, PUMA, and cell cycle regulator p21, showed concomitant upregulation with increasing concentrations of TAT-ZHPV18E6: 59. These findings indicate the functional restoration of the p53/p21 signaling pathway and the activation of the endogenous apoptotic machinery upon E6 inhibition. Restoration of the p53 tumor-suppressor pathway by TAT-ZHPV18E6: 59 in HPV18-positive HeLa229 cells. A Dose-dependent effects of TAT-ZHPV18E6: 59 on p53 stabilization and HPV18 E6 expression, NADPH was used as the loading control. B Restoration of p53 stability is associated with upregulation of the pro-apoptotic genes p21, Bax, and PUMA, and downregulation of anti-apoptotic gene Bcl-2. β-Actin served as the loading control. Protein expression was analyzed by Western blot after 48 h of treatment. Lane 1: PBS (mock); Lane 2: 20 µM TAT-Zwt (negative control); Lane 3: 5 µM TAT-ZHPV18E6: 59; Lane 4: 10 µM TAT-ZHPV18E6: 59; Lane 5: 20 µM TAT-ZHPV18E6: 59 Discussion HPV-associated CC remains a significant global health burden despite available preventive vaccines. HR-HPV types 16 and 18 collectively account for approximately 70% of CC cases worldwide (Kusakabe et al. 2023; Ramakrishnan et al. 2015). The well-documented association between persistent HPV infection and cervical carcinogenesis has led to two complementary interventions: prophylactic vaccines for primary infection and molecular therapies targeting HPV oncoproteins in established lesions. Although current vaccines show remarkable efficacy in primary prevention, therapeutic targeting of HPV oncoproteins remains a critical unmet clinical need, particularly for treating existing HPV-related malignancies. The carcinogenesis of HPV-related CC is primarily driven by the E6 and E7 oncoproteins of HR-HPV genotypes, which mediate progression from persistent infection to invasive carcinoma (Kusakabe et al. 2023; Hoppe-Seyler et al. 2018). In this study, functionally validated recombinant human papillomavirus 18 E6 served as the target antigen for our designed Affibody molecules. The HPV E6 oncoprotein, featuring its zinc-binding domains and a postsynaptic density protein 95/Drosophila disc large tumor suppressor/zonula occludens-1 (PDZ)-binding motif, represents a prime therapeutic target due to its essential roles in p53 degradation and cellular immortalization. Recent structural studies have defined the critical functional epitopes within E6 (Estêvão et al. 2019), facilitating the development of targeted inhibitors. In this study, functionally validated recombinant HPV18 E6 served as the target antigen for our designed Affibody molecules. Affibody technology has emerged as a powerful platform for targeting tumor-associated antigens and pathogenic proteins, with growing evidence supporting its diagnostic and therapeutic applications. Notably, Affibody molecules have been successfully engineered to target diverse pathogenic proteins, including EBV LMP1 (Zhu et al. 2020; Kamara et al. 2021), SARS-CoV-2 spike protein (Du et al. 2023), and Chlamydia trachomatis major outer membrane protein (MOMP) (Li et al. 2021). Our laboratory previously validated Affibody molecules with high binding affinity and specificity targeting both HPV16E6/E7 (Jiang et al. 2018; Zhu et al. 2018) and HPV18E7 proteins (Wang et al. 2019), demonstrating their potential in clinical oncology and infectious diseases. Building upon this foundation, the current study focused on the development of novel Affibody molecules targeting HPV18 E6. Through phage display screening, we successfully isolated high-affinity Affibody molecules targeting HPV18 E6. Given the intracellular localization of the E6 protein, we engineered the Affibody by fusing it with the TAT cell-penetrating peptide (Wang et al. 2014) to enhance cellular internalization (Fig. 2). TAT, enriched in basic amino acids, enables efficient intracellular translocation with minimal cytotoxicity (Mohammadi et al. 2021; Jeong et al. 2016). Molecular, cellular, and in vivo NIRF imaging analyses confirmed that the TAT-fused Affibody retains high affinity and specificity for HPV18E6 protein. Our results demonstrated that the engineeredTAT-ZHPV18E6 exhibited high binding affinity and potent targeting specificity, highlighting their potential for both diagnostic and therapeutic applications. HPV E6 and E7 oncoproteins drive carcinogenesis through complementary mechanisms: E6 mediates the degradation of p53, whereas E7 inactivates pRb (Vishnoi et al. 2016; Ferraz et al. 2022; Li et al. 2019). Our previous work identified TAT-ZHPV18E7: 228 as an effective inhibitor of cell proliferation (Wang et al. 2019). However, the potential synergistic effect of targeting both oncoproteins using TAT-ZHPV18E6: 59 in combination with TAT-ZHPV18E7: 228 remained to be elucidated. In the present study, we found that TAT-ZHPV18E6: 59 alone or in combination with TAT-ZHPV18E7: 228 significantly inhibited the proliferation of (HPV18+) HeLa229 cells. Dual targeting HPV18 E6/E7 Affibody molecules produced significantly enhanced cytotoxicity compared to single-agent treatments (CCK-8 assay, p < 0.01). This synergy was further confirmed by colony formation assays, where the combination treatment reduced clonogenic capacity by > 70% than either agent alone. Mechanistic studies revealed that TAT-ZHPV18E6: 59 significantly induced apoptosis in HeLa229 cells (flow cytometry, p < 0.01 vs. TAT-Zwt control) without altering cell cycle distribution. This suggests that the anti-proliferative effects primarily result from apoptosis induction rather than cell cycle arrest. We demonstrated that TAT-ZHPV18E6: 59 counteracts HPV18 E6-mediated p53 degradation, as evidenced by dose-dependent p53 stabilization and upregulation of its downstream targets Bax, PUMA, and p21 (Fig. 5). Notably, p21 upregulation may contribute to cell cycle arrest by inhibiting cyclin-dependent kinase (CDK) activity and reducing Rb phosphorylation, thereby partially restoring the Rb tumor suppressor pathway. Although direct Rb phosphorylation was not assessed in this study, this p53-p21-Rb axis provides a mechanistic link between p53 reactivation and the observed anti-proliferative effects. Further genetic validation, including p53 knockdown, is required to confirm the p53 dependency of the observed apoptosis. In summary, our results demonstrate that TAT-ZHPV18E6: 59 is a promising therapeutic candidate for HPV-related CC. It acts by blocking E6-mediated p53 degradation, restoring p53-dependent apoptosis, and exhibiting synergistic effects with E7-targeting agents. Although our NIRF imaging confirms specific tumor targeting and renal clearance of TAT-ZHPV18E6: 59, formal pharmacokinetic studies, long-term efficacy assessments, and combination index (CI) analysis are required to advance this Affibody toward clinical application. Author contributions Methodology, resources, visualization, data curation, formal analysis, and writing–original draft preparation: HD and JZ; software and validation: LW and XZ; resources, investigation, and data curation: JC, WD, and SK; conceptualization, supervision, project administration, writing-review and editing, and funding acquisition: SZ and LZ. All authors have read and agreed to the published version of the manuscript. Funding This research was supported by the National Natural Science Foundation of China General Program (Grant No. 81172463) and the Independent Research Project of Wenzhou Science and Technology Bureau (Grant No. Y2023072). Data availability The original contributions presented in the study are included in the article Supplementary Material. Further inquiries could be directed to the corresponding author. Declarations Ethics approval This study was carried out in strict compliance with the Guidelines for Experimental Animals established by the State Science and Technology Commission of China. All animal study protocols were approved by the Animal Experimental Ethics Committee of Wenzhou Medical University (Approval No. wydw2021-0585; valid from February 10 to July 20, 2021). Consent to participate Not applicable. Consent for publication All authors have read and approved the final manuscript. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Haiyan Dong and Jing Zhang contributed equally to this work. Contributor Information Shanli Zhu, Email: wenzhouzsl@126.com. Lifang Zhang, Email: wenzhouzlf@126.com. References Associated Data Data Availability Statement The original contributions presented in the study are included in the article Supplementary Material. Further inquiries could be directed to the corresponding author.